Varithena bottle with three white stripes in background

Real-world outcomes




Impressive results achieved time after time.

Proven results from more than 300,000 treatments performed by over 2,000 trained Varithena physicians. And there’s more on the way. 

Dr. Deak's 2018 publication

Objective: Evaluate safety and efficacy of Varithena among symptomatic patients with superficial chronic venous insufficiency.

Key results:

94.4% of patients reported symptom relief.1

Dr. Caurgo's 2016 study

Not all foam is created equal.

This study demonstrates the advantages of a pre-formulated foam compared to physician-compounded foam, why the former is more durable than the latter, and what that means for your patients.3

Polidocanol endovenous microfoam

Physician-compounded foam

Hear from a Varithena-trained physician.

At first, Dr. Juan Carlos Jimenez was skeptical of Varithena, but has since become a convert. Watch him speak about his experience, and his best practices.

Dr. Deak's 2021 publication

Objective: Evaluate outcomes among symptomatic patients with superficial venous insufficiency treated with Varithena or endovenous laser ablation (EVLA).

Key results:

Elimination of reflux was 93.5% and 92.8% of the Varithena and EVLA-treated patients.2

“Due to the tortuosity of the patient’s anatomy, Varithena gave me the best option to improve the patients’ symptoms and allow him to return to work with minimal downtime.”

- Ajit Naidu, MD

Blue teal striped background

Change in IPR-V3 score

IPR-V3:  independent photography review of visible varicose veins

Dr. Vasquez's 2017 study

Key results: ETA and Varithena eliminated reflux through the SFJ in 87.3% of patients compared to 78.9% in ETA alone.4

Read how using Varithena with endovenous thermal ablation (ETA) yielded better results than using ETA alone, including lower retreatment rates and a higher percentage of patients with eliminated reflux.

Dr. Jimenez 2021 publication

With the use of these adjunctive techniques, this study demonstrated minimal deep venous thrombotic adverse events following microfoam ablation and lower ATE’s than reported in early Phase III clinical trials.5


Non-occlusive extension of thrombus into the deep system

finger pointing icon


Add to your practice with this versatile, efficient, and consistent varicose vein treatment. Order directly from Boston Scientific.

Circle with checkmark icon

Become Varithena certified

Join the 2,000+ certified physicians improving patients’ lives with Varithena. We’re here to help you, and becoming certified is easy.

person icon

Contact a sales representative

Have your local Varithena
sales representative
contact you.

magnifying glass icon

Join the physician

Patients want to know who’s performing Varithena procedures. Get noticed by potential patients. 


  1. Deak, Steven T. “Retrograde Administration of Ultrasound-Guided Endovenous Microfoam Chemical Ablation for the Treatment of Superficial Venous Insufficiency.” Journal of Vascular Surgery: Venous and Lymphatic Disorders, vol. 6, no. 4, July 2018, pp. 477–484., doi: The author is a consultant for Boston Scientific.
  2. Deak ST. Treatment of superficial venous insufficiency in a large patient cohort with retrograde administration of ultrasound-guided polidocanol endovenous microfoam versus endovenous laser ablation. J Vasc Surg Venous Lymphat Disord. 2021 Dec 24:S2213-333X(21)00609-0. doi: 10.1016/j.jvsv.2021.11.007. Epub ahead of print. PMID: 34958977.
  3. Carugo D, Ankrett DN, Zhao X, et al. Phlebology: May 2016; 31(4):283-95.
  4. Vasquez, Michael. “A multicenter, randomized, placebo-controlled trial of endovenous thermal ablation with or without polidocanol endovenous microfoam treatment in patients with great saphenous vein incompetence and visible varicosities.” Phlebology.2017 May;32(4):272-281. doi: 10.1177/0268355516637300. The author is a consultant for Boston Scientific.
  5. Jimenez JC, et al. Adjunctive techniques to minimize thrombotic complications following microfoam sclerotherapy of saphenous trunks and tributaries. J Vasc Surg Venous Lymphat Disord. 2021 Jul;9(4):904-909. Epub 2020 Nov 26. PMID: 33248297


Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins,  accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Important Safety Information

The use of Varithena® is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena®.

See Full Prescribing Information for Varithena®

Varithena™ is a registered trademark of Boston Scientific. All other trademarks are property of their respective owners.